Gilead Sciences (DB:GIS) - Stock Price, News & Analysis

GIS Stock Overview

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

About the company

GIS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	3/6
Dividends	2/6

Rewards

Trading at 61.8% below our estimate of its fair value

Earnings are forecast to grow 35.87% per year

Risk Analysis

Has a high level of debt

Dividend of 3.62% is not well covered by earnings

Large one-off items impacting financial results

Profit margins (3.8%) are lower than last year (20%)

Gilead Sciences, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

Merck KGaA

XTRA:MRK

€68.8b

Formycon

XTRA:FYB

€897.0m

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$109.6b

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share Price	US$77.65
52 Week High	US$80.08
52 Week Low	US$57.58
Beta	0.20
11 Month Change	4.42%
3 Month Change	20.61%
1 Year Change	4.37%
33 Year Change	36.23%
5 Year Change	32.76%
Change since IPO	471.27%

Recent updates

Shareholder Returns

	GIS	DE Biotechs	DE Market
7D	0.2%	-0.3%	0.8%
1Y	4.4%	-12.1%	14.0%

Return vs Industry: GIS exceeded the German Biotechs industry which returned -12.1% over the past year.

Return vs Market: GIS underperformed the German Market which returned 14% over the past year.

Price Volatility

Is GIS's price volatile compared to industry and market?
GIS volatility
GIS Average Weekly Movement	3.3%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.5%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: GIS has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: GIS's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1987	18,000	Dan O'Day	www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GIS fundamental statistics
Market cap	€96.99b
Earnings (TTM)	€966.62m
Revenue (TTM)	€25.50b

100.5x

P/E Ratio

3.8x

P/S Ratio

Is GIS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GIS income statement (TTM)
Revenue	US$27.81b
Cost of Revenue	US$6.27b
Gross Profit	US$21.53b
Other Expenses	US$20.48b
Earnings	US$1.05b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 06, 2024

Earnings per share (EPS)	0.85
Gross Margin	77.44%
Net Profit Margin	3.79%
Debt/Equity Ratio	128.3%

How did GIS perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

360%

Payout Ratio

GIS Stock Overview

Rewards

Risk Analysis

Gilead Sciences, Inc. Competitors

XTRA:BIO3

€1.4b

XTRA:MRK

€68.8b

XTRA:FYB

€897.0m

NasdaqGS:REGN

US$109.6b

Price History & Performance

Recent News & Updates

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Upcoming dividend of US$0.77 per share

Second quarter dividend of US$0.77 announced

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Second quarter 2024 earnings released: EPS: US$1.29 (vs US$0.84 in 2Q 2023)

Recent updates

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Upcoming dividend of US$0.77 per share

Second quarter dividend of US$0.77 announced

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Second quarter 2024 earnings released: EPS: US$1.29 (vs US$0.84 in 2Q 2023)

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings released: US$3.34 loss per share (vs US$0.81 profit in 1Q 2023)

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Full year 2023 earnings released: EPS: US$4.54 (vs US$3.66 in FY 2022)

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Fourth quarter dividend of US$0.77 announced

New minor risk - Financial position

Full year 2023 earnings released: EPS: US$4.54 (vs US$3.66 in FY 2022)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Upcoming dividend of US$0.75 per share at 3.8% yield

New minor risk - Financial position

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$1.75 (vs US$1.43 in 3Q 2022)

Shareholder Returns

Price Volatility

About the Company

Gilead Sciences, Inc. Fundamentals Summary

100.5x

3.8x

Earnings & Revenue

Dividends

3.6%

360%